ROIV Roivant Sciences Ltd
Company Analysis
Latest News
🔴 Roivant Sciences is trading 4.21% down as AI spending concerns weighed on markets
Roivant Sciences is trading at $36.62, down 4.21%, in a move most consistent with broad risk-off selling amid investor concerns about AI spending and scrutiny...
🟢 Roivant Sciences is trading 4.3% up today on Phase 3 brepocitinib results in noninfectious uveitis
Roivant Sciences is trading at $37.58, up 4.27%, as Benzinga attributes Wednesday’s jump to Phase 3 CLARITY results showing brepocitinib treated noninfectious...
🔴 Roivant Sciences is trading 8.19% down in pre-market with no clear catalyst identified
Roivant Sciences is trading at $33.50, down 8.19% in pre-market; no fresh company announcement explains the decline. - Latest major company news was positive...
🟢 Roivant Sciences is trading 5% up today after brepocitinib met both Phase 3 primary endpoints
Roivant Sciences is trading at $36.68, up 5.04%, after brepocitinib met primary endpoints in both Phase 3 CLARITY trials for non-infectious uveitis. - At Week...
🟢 Roivant Sciences is trading 10.5% up in pre-market after brepocitinib met primary endpoints in both trials
Roivant Sciences is trading at $38.60, up 10.54%, after positive Phase 3 results for brepocitinib in non-infectious uveitis. - CLARITY-1 and CLARITY-2 met...
Roivant Announces Positive Phase 3 Trial Results for Brepocitinib in Non-Infectious Uveitis
Roivant Sciences and its subsidiary Priovant Therapeutics announced positive results from the Phase 3 CLARITY program for its drug, brepocitinib, in treating...
Roivant's Eye-Disease Drug Aces Two Late-Stage Trials — But Can a $27 Billion Biotech Keep Delivering Without Revenue?
Shares surged 7.6% to $37.56 as Roivant Sciences delivered dual Phase 3 wins this morning for its lead anti-inflammatory drug in a rare eye disease,...
🟢 Roivant Sciences is trading 7.6% up in pre-market after positive Phase 3 brepocitinib results
Roivant Sciences is trading at $37.56, up 7.56%, as its recent announcements are the clearest explanation for pre-market strength. - The company announced...
🟢 Roivant Sciences is trading 4.53% up today amid a biotech-sector M&A tailwind
Roivant Sciences is trading at $35.05, up +4.53%, as biotech-sector momentum may be helping; no company-specific catalyst was identified. - No Roivant-specific...
🟢 Roivant Sciences is trading 23.22% up in after-hours trading; catalyst remains unclear
Roivant Sciences is trading at $41.32, up 23.22%, with the after-hours catalyst unclear. - No verified October 16 company-specific announcement surfaced to...
🟢 Roivant Sciences is trading 4.59% up in pre-market on October 14, 2026; catalyst remains unclear
Roivant Sciences is trading at $34.88, up 4.59%, with the catalyst for the pre-market move unclear. - No verified overnight company announcement or report...
🔴 Roivant Sciences is trading 4% down today as oil and Treasury yields stoke inflation concerns
Roivant Sciences is trading at $33.35 (-4.03%) amid broad risk-off sentiment as higher oil prices and Treasury yields raise inflation concerns. - Reuters...
🔴 Roivant Sciences is trading 5% down in pre-market
Roivant Sciences is trading down 5.06% in pre-market at $32.99 on October 8, with no clear company-specific announcement identified as the cause. - It closed...
Roivant Boosts Finances with $950 Million Moderna Patent Settlement
Roivant Sciences subsidiary Genevant Sciences and Arbutus Biopharma received a $950 million upfront payment from Moderna to settle a patent-infringement...
Roivant, Immunovant Halt Lupus Drug Development After Trial Misses Main Goal
Roivant Sciences and its majority-owned subsidiary Immunovant are discontinuing the development of their experimental drug, IMVT-1402, for treating cutaneous...
🟢 Roivant Sciences rises 4.1% — Biotech Sector Surges in Pre-Market on Multiple Positive News Snippets
With Biotech (XBI) up 2.6%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Roivant Sciences is trading 24% down today in after-hours trading with no specific negative announcement identified
Roivant Sciences is trading 23.81% lower at $29.12 after-hours on September 22, 2026, versus the regular-session close of $38.22; available coverage identifies...
🔴 Roivant Sciences is trading 24.49% down in after-hours trading amid possible after-hours liquidity or data anomaly
Roivant Sciences is trading at $30.03, down 24.49% after closing at $39.77 on September 18, 2026; the move may reflect an after-hours liquidity or data anomaly...
Roivant Sciences Rises, Stifel Sets $51 Target on Autoimmune Pipeline
Stifel initiated coverage on Roivant Sciences (ROIV) with a Buy rating and a $51.00 price target. The firm identifies a multi-asset opportunity within...
🔴 Roivant Sciences falls 4.1% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...